Vaccine Therapy in Treating Patients With Metastatic Melanoma
Maneno muhimu
Kikemikali
Maelezo
OBJECTIVES:
Primary
- Determine clinical response in HLA-A *0201-positive patients with metastatic melanoma treated with an intradermally administered vaccine comprising autologous dendritic cells pulsed with MART-1, gp100, and tyrosinase peptides and matured with a cytokine cocktail.
Secondary
- Determine immunologic response in patients treated with this regimen.
OUTLINE: This is a multicenter study.
Patients undergo apheresis to collect dendritic cells (DC). Autologous DC are pulsed ex vivo with tumor antigen peptides derived from MART-1: 26-35 (27L), gp100: 209-217 (210M), and tyrosinase: 368-376 (370D) and matured with a cytokine cocktail comprising interleukin (IL)-4, IL-6, IL-1β, sargramostim (GM-CSF), tumor necrosis factor-α, and prostaglandin E2.
Patients receive 12 intradermal injections of DC vaccine over 30 minutes on days 1, 8, 22, and 36. Treatment repeats every 8 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed periodically until disease progression.
PROJECTED ACCRUAL: A total of 41 patients will be accrued for this study.
Tarehe
| Imethibitishwa Mwisho: | 04/30/2014 |
| Iliyowasilishwa Kwanza: | 06/06/2006 |
| Uandikishaji uliokadiriwa Uliwasilishwa: | 06/06/2006 |
| Iliyotumwa Kwanza: | 06/07/2006 |
| Sasisho la Mwisho Liliwasilishwa: | 05/18/2014 |
| Sasisho la Mwisho Lilichapishwa: | 05/20/2014 |
| Tarehe halisi ya kuanza kwa masomo: | 09/30/2003 |
| Tarehe ya Kukamilisha Msingi iliyokadiriwa: | 05/31/2005 |
| Tarehe ya Kukamilisha Utafiti: | 05/31/2005 |
Hali au ugonjwa
Uingiliaji / matibabu
Biological: MART-1 antigen
Biological: gp100:209-217(210M) peptide vaccine
Biological: therapeutic autologous dendritic cells
Biological: tyrosinase peptide
Awamu
Vigezo vya Kustahiki
| Zama zinazostahiki Kujifunza | 16 Years Kwa 16 Years |
| Jinsia Inastahiki Kujifunza | All |
| Hupokea Wajitolea wa Afya | Ndio |
| Vigezo | DISEASE CHARACTERISTICS: - Diagnosis of melanoma - Metastatic disease - The following melanoma subtypes are eligible: - Unresectable, stage III-IV uveal melanoma - Metastatic mucosal melanoma - Measurable disease after attempted curative surgical therapy - Tumor tissue must be available for immunohistochemical staining - Positive for ≥ 1 of the following peptides: - MART-1: 26-35 (27L) - gp100: 209-217 (210M) - Tyrosinase: 368-376 (370D) - HLA-A *0201 positive by DNA polymerase chain reaction assay PATIENT CHARACTERISTICS: - ECOG performance status (PS) 0-1 OR Karnofsky PS 70-100% - Creatinine ≤ 2.0 mg/dL - Bilirubin ≤ 2.0 mg/dL - WBC ≥ 3,000/mm^3 - Platelet count ≥ 75,000/mm^3 - Hemoglobin ≥ 9.0 g/dL - No major systemic infections - No coagulation disorders - No major medical illness of the cardiovascular or respiratory system - No myocardial infarction within the past 6 months - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No known HIV positivity - No know positivity for hepatitis B surface antigen or hepatitis C antibody - No prior uveitis or autoimmune inflammatory eye disease - No other prior malignancy except cervical carcinoma in situ or basal cell skin cancer unless patient was curatively treated > 5 years ago and has no detectable disease PRIOR CONCURRENT THERAPY: - See Disease Characteristics - No more than 1 prior cytotoxic chemotherapy agent or regimen - Prior biologic or antiangiogenic therapies allowed - More than 1 month since prior and no concurrent radiotherapy, chemotherapy, adjuvant therapy, or any other therapy for melanoma - No prior MART-1: 26-35 (27L), gp100: 209-217 (210M), or tyrosinase: 368-376 (370D) peptides - No concurrent steroid therapy |
Matokeo
Hatua za Matokeo ya Msingi
1. Overall survival [undefined]
2. Progression-free survival [undefined]
3. Time to progression [undefined]
4. Toxicity [undefined]
